Related Experiment Video
Updated: May 2, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.2K
[Oral anticoagulation for atrial fibrillation]
Matthias Antz1, Joelle Beauport, Wolfgang Vocke
1Herz- und Gefäßzentrum, Klinik für Kardiologie, Klinikum Oldenburg gGmbH, Rahel-Straus-Str. 10, 26133, Oldenburg, Deutschland, antz.matthias@klinikum-oldenburg.de.
Herzschrittmachertherapie & Elektrophysiologie
|February 25, 2014
Summary
Optimizing anticoagulation for atrial fibrillation patients is crucial. New guidelines and direct oral anticoagulants (DOACs) improve prevention of thromboembolic events and reduce complications.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Context:
- Atrial fibrillation (AF) necessitates effective anticoagulation to prevent thromboembolic events.
- Current guideline adherence for anticoagulation in AF patients is suboptimal.
- Direct oral anticoagulants (DOACs) represent a significant advancement over traditional vitamin K antagonists.
Purpose:
- To review current guidelines and evidence for appropriate anticoagulation in AF.
- To highlight the role of DOACs in optimizing thromboembolic event prevention.
- To reduce complications associated with anticoagulation therapy in AF.
Summary:
- The abstract emphasizes the critical need for correct oral anticoagulation in patients with atrial fibrillation (AF) to prevent thromboembolic events.
- It notes that anticoagulation is not always managed according to established guidelines.
- The introduction of direct oral anticoagulants (DOACs) offers a modern alternative to vitamin K antagonists, with new European Society of Cardiology (ESC) and European Heart Rhythm Association (EHRA) guidelines aiding their appropriate use.
Impact:
- Improved patient outcomes through optimized thromboembolic event prevention in AF.
- Reduced incidence of anticoagulation-related complications.
- Enhanced clinical practice through adherence to updated ESC and EHRA guidelines on DOACs for AF management.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.8K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.8K
01:25Dysrhythmias VI: Management of Dysrhythmias
597
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
597
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K